Only one in 10 treatments for lower back pain ‘are effective'
The majority of treatments for lower back pain may not be effective, according to a new review.
While the NHS advises that back pain will usually improve 'within a few weeks', this may seem like a lifetime to sufferers who will look for ways to alleviate their pain.
But a new study has found that only one in 10 treatments for lower back pain are effective, with those that improve symptoms only having 'slight' or 'small' effects on pain.
Experts found that evidence was 'inconclusive' for a number of popular treatments.
Researchers led by academics in Australia set out to examine the effectiveness of non-surgical back pain treatments in adults.
They looked at 301 trials examining 56 different treatments for lower back pain.
People involved with the studies reported pain intensity at the start of the trial and again after treatment.
Researchers also assessed the certainty of the evidence provided in the studies.
They found that just one treatment for acute low back pain and five treatments for chronic – or long-term – back pain were 'efficacious'.
These include non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, for short-term back pain.
For long-term back pain the treatments found to be effective were exercise, spinal manipulative therapy, taping, antidepressants and a type of drug called transient receptor potential vanilloid 1 (TRPV1).
But even these were only found to have 'slight' or 'small' reductions in pain compared with a placebo – or dummy drug.
'Best available evidence shows that one in 10 common non-surgical and non-interventional treatments for low back pain are efficacious, providing small analgesic effects beyond placebo,' the authors said.
They said that exercise, paracetamol and glucocorticoid injections 'probably provides little to no difference in pain' for acute lower back issues.
Antibiotics and anaesthetics were also found to be 'not efficacious' for long-term lower back problems.
Meanwhile the rest of the interventions studied had 'inconclusive evidence' so the authors called for more studies to examine the 'remaining uncertainty' surrounding a number of back pain treatments.
While the evidence was deemed to be inconclusive, the information available did point to some of these being effective for acute back pain.
For example the authors found that the certainty of the evidence for acupuncture was 'low' but the information that is available suggests that it may provide moderate reductions in pain for both short and long-term back pain.
And while massage is said to have large reductions in pain, the evidence surrounding this claim is 'very low'.
Other interventions where the evidence was deemed to be inconclusive include heat, TENS, opioids and muscle relaxants.
The authors, writing in BMJ Evidence-Based Medicine, added: 'Most non-surgical and non-interventional treatments for low back pain were not efficacious.
'Around 10% of non-surgical and non-interventional treatments provided small analgesic effects beyond placebo.
'For acute low back pain, there is moderate certainty evidence that NSAIDs are efficacious.
'For chronic low back pain, there is moderate certainty evidence that exercise, spinal manipulative therapy, taping, antidepressants, and TRPV1 agonists are efficacious.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
North Wales Chronicle
4 hours ago
- North Wales Chronicle
Weight loss jabs could be transformative, says outgoing NHS England official
Cholesterol-busting statins are one of the most commonly prescribed drugs in the UK, with around seven to eight million people taking them to cut their chance of heart attack and stroke. An estimated 1.5 million are taking weight loss jabs in the UK. Professor Sir Stephen Powis, the outgoing medical director of NHS England, said the NHS needs to go 'further and faster' to 'turn the tide' on rising levels of obesity. Later this month GPs in England will be allowed to prescribe mounjaro, also known as tirzepatide, for the first time. Patients previously needed to access the drugs through a special weight loss service. Speaking at the NHS ConfedExpo conference in Manchester, Sir Stephen hailed the rollout in GP surgeries as an 'exciting milestone' and said NHS officials are also examining ways to 'broaden access to the drugs'. Around 29% of adults in the UK are obese. Sir Stephen said: 'Right now, obesity is estimated to cost the NHS approximately £11.4 billion every year – this financial burden is unsustainable for the NHS and wider economy. 'We have to turn the tide. We have to and will go further, and faster. 'In just a few years from now, some of today's weight loss drugs will be available at much lower cost. This could completely transform access to these innovative treatments. 'But we will and must be guided by the evidence base and must do this safely and sustainably, in a way that ensures that we are equipped as a health service to deal with the demand.' He said he is not 'starry-eyed' about weight loss drugs, adding they are 'no silver bullet'. He told reporters: 'These medicines can be harmful if they are prescribed without the right checks and wraparound care – they can have side effects, including nausea, dehydration and inflammation of the pancreas, and a worrying number of people are continuing to access them without appropriate checks via the internet. 'We are ambitious and determined to explore different methods of delivery and strengthen the evidence base and will do so alongside this phased rollout, but this is a historic first step in widening access, with 220,000 people set to benefit from the rollout over the first three years. 'So I think over time it's highly likely that they will become more widespread, the evidence base will increase, we will learn better how to deploy them, we'll learn how long people need to be on them, and in terms of weight reduction, how much weight reduction is maintained once people come off – that's a big unknown. 'We see this every time we have a new class of drugs in the early days. But there's still much more to learn. 'There will be more drugs coming on the market; there will be different prices for drugs, we will get to generics, which means that prices will fall. 'We have been through this with statins, and the use of statins is now very different from when they first came out, and I've no doubt that will be the same for these drugs. 'So it's very exciting, but we're in the foothills of learning how to use them.' Asked about statins, Sir Stephen said: 'So firstly, obesity is associated with a whole set of conditions (such as) kidney disease, cardiovascular disease, respiratory conditions. 'So in reducing weight, you will, by the very nature of doing that, be reducing the risk of a whole set of difficult conditions and aiding with their management where people already have them. 'Whether the drugs have effects beyond that, I think, is a research question, and there will be an evidence base being generated. 'And it's not completely unusual for drugs over time to be found to have effects that go over and beyond what they were initially designed for. 'So I think we will wait and see. But obviously, the first task, amongst all the excitement and all the discussion and debate, is to actually get on and deploy tirzepatide in particular. 'We have been focused on getting this rolled out by the end of this month… and that is going to be a really exciting milestone. 'It's going to be a very exciting journey, and there will be things on the way that we haven't expected.' He added: 'We set out the our plan for uptake – Nice (National Institute for Health and Care Excellence) have asked for a review of that after three years, which is quite right, because it's quite a long horizon. 'Cost is one element of that, but I think we will learn more about the outcomes that these drugs are driving in terms of lower cardiovascular events and reducing the conditions that we know associated with obesity. 'So absolutely, cost is one element of that, but it's not the only element. We want to look carefully at what the science tells us.' Sir Stephen added: 'When I look back when dialysis came in, we didn't use dialysis for older people. Over years the technology improved, we got more confident, more people were able to access the treatment. 'So we've much to learn with these drugs. It's a really exciting time.' He went on: 'We want to broaden the ways in which you can access these drugs – so we're very interested in thinking about pharmacies, thinking about digital. 'We will deliver the structured support through a combination of digital and face-to-face. 'But we want to innovate. This can be a model that is not just about GP prescribing, but we need to learn how to do that.'
The Independent
4 hours ago
- The Independent
Hospitals could run GP surgeries under NHS reforms
Hospitals could take over GP surgeries and family doctors could run hospitals under radical plans to reform the NHS in England. Wes Streeting said the forthcoming 10 year health plan would also see 'much of what's done in a hospital today, will be done on the high street'. But he stressed the Government was 'not embarking on another top-down reorganisation' of the health service. The plan is expected to be published in July. Speaking at the NHS ConfedExpo conference in Manchester, Mr Streeting said: 'The NHS should not be bound by traditional expectations of how services should be arranged. 'I am open to our strongest acute trusts providing not just community services, as many already do, but also primary care. 'Whatever services will enable them to meet the needs of their patients in a more integrated and efficient way. 'Indeed, I would hope that those old-fashioned labels – acute, community – become increasingly meaningless. 'Likewise, there is no reason why successful GPs should not be able to run local hospitals, or why nurses should not be leading neighbourhood health services.' Mr Streeting talked about the 'jeopardy' facing the NHS, adding: 'Just as public satisfaction has plunged to its lowest level on record, major political parties have begun to question the very existence of a publicly funded universal healthcare system free at the point of need. 'And I can almost feel them willing us on to fail, because if all of us fail in our mission to turn the NHS around, the vultures on the populist rivals swoop in for the kill. 'The NHS is in a fight for its life but nothing I have experienced in my first 11 months in office have shaken my conviction or confidence that this is a fight we will win.' Meanwhile he spoke about the spending review, likening himself to the survivor in the popular book series, The Hunger Games. 'Yesterday's spending review was a vital moment on that journey,' he said. 'There have been broadly two sorts of reactions to this. The first, mainly from the media and the public – '£29 billion is a hell of a lot of money'; the second, mainly from our think tank friends – '£29 billion is nowhere near enough'. The truth is, both are right. 'It is objectively a substantial funding settlement that puts wind in our sails. But investment alone isn't enough. 'There is no fix to the NHS's problems that simply pours more money into a broken system. 'It is only through the combination of investment and reform that we will succeed in getting the NHS back on its feet and making make it fit for the future.' He told delegates at the conference: 'Despite my best efforts at the Cabinet yesterday morning before the spending review announcement, to put the blame on John Healey the Defence Secretary for the squeeze on other government departments, none of my colleagues were buying. 'In fact, one permanent secretary once referred to me as the Katniss Everdeen of The Hunger Games. 'We're a Labour Government – the NHS is all of our priorities, and there isn't a single person sat with me around the Cabinet table who doesn't value what you're doing, doesn't underestimate the scale of the task that we have ahead of us, and they are all rooting for us to succeed, every single one of them.' Commenting on the speech, Matthew Taylor, chief executive of the NHS Confederation, said: 'The Secretary of State is right that the divides between acute, primary, community are already being broken down, supported by the work of integrated care boards. 'Redesigning services is essential to the future of the NHS and many providers are already breaking down their traditional silos to offer patients truly personalised and integrated care.' He added: 'The extra funding announced at the spending review is very welcome and, as Mr Streeting says, it is both a lot of money and not enough. 'Many of our members have warned they will not hit the interim target, with only one in two confident they will achieve the 65% elective care interim target by March 2026. 'That is why redesigning services is so essential – the combination of investment and reform – so that we can achieve the Government's three ambitions.'
The Independent
4 hours ago
- The Independent
Wes Streeting to announce radical reforms to NHS services
Health Secretary Wes Streeting is set to announce radical reforms for the NHS in England, potentially including hospitals taking over GP surgeries and family doctors running hospitals. The 10-year plan, expected to be published in July, aims to shift many hospital services to high streets, but Streeting insists it is not a "top-down reorganisation". Streeting emphasised the need to break down traditional service arrangements, suggesting acute trusts could provide primary care and GPs could manage local hospitals. Streeting acknowledged the "jeopardy" facing the NHS, noting declining public satisfaction and questioning of its funding model, while expressing confidence in turning the situation around. The recent spending review allocated £29 billion to the NHS, which Streeting described as substantial but insufficient without accompanying reforms to address systemic issues.
